Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742232 | 1.00 | FOLH1 (0.49) | FOLH1DGAT1 | |
| SCHEMBL29714503 | 0.90 | TDP1 (0.41) | — | |
| SCHEMBL19756829 | 0.84 | TDP1 (0.39) | — | |
| SCHEMBL23067828 | 0.83 | TBXAS1 (0.38) | — | |
| SCHEMBL29129053 | 0.81 | KMT2A (0.47) | — | |
| SCHEMBL29613413 | 0.81 | TDP1 (0.52) | — | |
| SCHEMBL18135317 | 0.80 | KMT2A (0.43) | — | |
| SCHEMBL29750399 | 0.79 | NOD1 (0.47) | — | |
| SCHEMBL22712971 | 0.76 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL18145839 | 0.76 | FOLH1 (0.67) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4249005-A2 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3493856-B1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | CORNELL UNIVERSITY (US) | 2022-06-23 | — | — | US | disclosed |
| US-20200317588-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | CORNELL UNIVERSITY (US) | 2020-10-08 | — | — | US | disclosed |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317588-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | VIP, CALCA, GLP1R | FOLH1 33/4885DGAT1 4569/4885 |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | FOLH1 2/4885DGAT1 4251/4885 |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | FOLH1 2/4885DGAT1 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.